Cargando…
Relugolix: A Review in Advanced Prostate Cancer
Relugolix (Orgovyx(®)), an orally active nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that provides rapid testosterone suppression, is indicated in the USA for the treatment of advanced prostate cancer and in the EU for advanced hormone-sensitive prostate cancer. In the pivot...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198864/ https://www.ncbi.nlm.nih.gov/pubmed/36652173 http://dx.doi.org/10.1007/s11523-022-00944-4 |
_version_ | 1785044820107984896 |
---|---|
author | Shirley, Matt |
author_facet | Shirley, Matt |
author_sort | Shirley, Matt |
collection | PubMed |
description | Relugolix (Orgovyx(®)), an orally active nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that provides rapid testosterone suppression, is indicated in the USA for the treatment of advanced prostate cancer and in the EU for advanced hormone-sensitive prostate cancer. In the pivotal phase III HERO trial in men with advanced prostate cancer, once-daily oral relugolix (with a loading dose on day 1) led to a sustained castration rate over 48 weeks of treatment of > 90%, a rate that was non-inferior to that provided by intramuscular leuprolide depot every 3 months (with an exploratory analysis further indicating the superiority of relugolix over leuprolide). Relugolix was generally well tolerated, having an adverse event profile that is consistent with testosterone suppression. Furthermore, there is evidence that relugolix may be associated with a lower risk of major adverse cardiac events compared with leuprolide. With the ability to provide the rapid testosterone suppression (with no initial surge in testosterone upon treatment initiation) combined with the benefits of oral administration and potentially improved cardiac safety, relugolix presents a valuable treatment option for men with advanced prostate cancer where androgen deprivation therapy is indicated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11523-022-00944-4. |
format | Online Article Text |
id | pubmed-10198864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-101988642023-05-21 Relugolix: A Review in Advanced Prostate Cancer Shirley, Matt Target Oncol Adis Drug Evaluation Relugolix (Orgovyx(®)), an orally active nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that provides rapid testosterone suppression, is indicated in the USA for the treatment of advanced prostate cancer and in the EU for advanced hormone-sensitive prostate cancer. In the pivotal phase III HERO trial in men with advanced prostate cancer, once-daily oral relugolix (with a loading dose on day 1) led to a sustained castration rate over 48 weeks of treatment of > 90%, a rate that was non-inferior to that provided by intramuscular leuprolide depot every 3 months (with an exploratory analysis further indicating the superiority of relugolix over leuprolide). Relugolix was generally well tolerated, having an adverse event profile that is consistent with testosterone suppression. Furthermore, there is evidence that relugolix may be associated with a lower risk of major adverse cardiac events compared with leuprolide. With the ability to provide the rapid testosterone suppression (with no initial surge in testosterone upon treatment initiation) combined with the benefits of oral administration and potentially improved cardiac safety, relugolix presents a valuable treatment option for men with advanced prostate cancer where androgen deprivation therapy is indicated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11523-022-00944-4. Springer International Publishing 2023-01-18 2023 /pmc/articles/PMC10198864/ /pubmed/36652173 http://dx.doi.org/10.1007/s11523-022-00944-4 Text en © Springer Nature 2023, corrected publication 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Adis Drug Evaluation Shirley, Matt Relugolix: A Review in Advanced Prostate Cancer |
title | Relugolix: A Review in Advanced Prostate Cancer |
title_full | Relugolix: A Review in Advanced Prostate Cancer |
title_fullStr | Relugolix: A Review in Advanced Prostate Cancer |
title_full_unstemmed | Relugolix: A Review in Advanced Prostate Cancer |
title_short | Relugolix: A Review in Advanced Prostate Cancer |
title_sort | relugolix: a review in advanced prostate cancer |
topic | Adis Drug Evaluation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198864/ https://www.ncbi.nlm.nih.gov/pubmed/36652173 http://dx.doi.org/10.1007/s11523-022-00944-4 |
work_keys_str_mv | AT shirleymatt relugolixareviewinadvancedprostatecancer |